Physician profile
Subhro K Sen
NPI 1669524559
$105,065.52
in general payments reported to CMS, 2019-2025
21 companies · $1,574 in 2025
The $1,574 reported for 2025 was more than what 81% of Plastic Surgery providers received nationally (typical 2025 total: $380).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,047 · 2020: $432 · 2021: $479 · 2022: $45K · 2023: $41K · 2024: $14K · 2025: $1,574.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $49K · Food and Beverage: $4,437 · Travel and Lodging: $2,942.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $49,497.50 |
| Food and Beverage | $4,437.11 |
| Travel and Lodging | $2,941.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Valencia Technologies Corporation | $96,356.05 | 2022-2024 | Ecoin Device Kit |
| Acumed LLC | $2,764.73 | 2019-2025 | Acumed, Inframe Implant, Innate Implant |
| Axogen | $2,093.61 | 2019-2025 | Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Cap |
| Kci USA, INC. | $904.10 | 2019 | |
| Musculoskeletal Transplant Foundation INC. | $608.97 | 2020-2023 | |
| Ethicon US, LLC | $560.00 | 2025 | Vicryl |
| Aroa Biosurgery Incorporated | $167.24 | 2024 | |
| Abbvie INC. | $149.65 | 2025 | |
| Tenex Health INC. | $147.87 | 2021 | |
| Extremity Medical | $146.94 | 2022 | |
| Tela Bio, INC. | $142.85 | 2025 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
| Endo Pharmaceuticals INC. | $137.00 | 2024 | Xiaflex |
| Mimedx Group, INC. | $132.92 | 2024 | |
| Bioventus LLC | $122.29 | 2019 | |
| Alafair Biosciences, INC. | $121.11 | 2024 | Versawrap |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Checkpoint Surgical, INC | $121.04 | 2022-2023 | Checkpoint Stimulators |
| Depuy Synthes Sales INC. | $115.79 | 2019 | |
| Stryker Corporation | $107.36 | 2019 | |
| Acell, INC. | $94.26 | 2019 | |
| Davol INC. | $50.00 | 2021 | |
| Smith+Nephew, INC. | $21.74 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$290,382.90 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Subhro Sen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.